loadpatents
Patent applications and USPTO patent grants for HOFMANN; Marco Hans.The latest application filed is for "anticancer combination therapy".
Patent | Date |
---|---|
Anticancer Combination Therapy App 20220249492 - GMACHL; Michael ;   et al. | 2022-08-11 |
Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors Grant 11,213,520 - Engelhardt , et al. January 4, 2 | 2022-01-04 |
Anti-cancer combination therapy Grant 11,198,726 - Hilberg , et al. December 14, 2 | 2021-12-14 |
Novel Benzylamino Substituted Pyridopyrimidinones And Derivatives As Sos1 Inhibitors App 20210009588 - RAMHARTER; Juergen ;   et al. | 2021-01-14 |
New Phenylpyrazolylacetamide Compounds And Derivatives As Cdk8/cdk19 Inhibitors App 20190290637 - ENGELHARDT; Harald ;   et al. | 2019-09-26 |
Novel Benzylamino Substituted Pyridopyrimidinones And Derivatives As Sos1 Inhibitors App 20190194192 - RAMHARTER; Juergen ;   et al. | 2019-06-27 |
Anti-cancer Combination Therapy App 20180346559 - Hilberg; Frank ;   et al. | 2018-12-06 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.